IL114409A - A method of increasing the effective percentage of weight in animals after slaughter in the final stage of breeding - Google Patents

A method of increasing the effective percentage of weight in animals after slaughter in the final stage of breeding

Info

Publication number: IL114409A
Authority: IL; Israel
Prior art keywords: bovine; somatotropin; bst; period; cattle
Prior art date: 1994-07-01

Application number

IL11440995A

Other languages

English (en)

Hebrew (he)

Other versions

IL114409A0 (en

Original Assignee

Monsanto Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-01

Filing date

1995-06-30

Publication date

1998-12-27

1995-06-30 Application filed by Monsanto Co filed Critical Monsanto Co

1995-10-31 Publication of IL114409A0 publication Critical patent/IL114409A0/xx

1998-12-27 Publication of IL114409A publication Critical patent/IL114409A/en

Links

241000283690 Bos taurus Species 0.000 title claims description 85
235000015278 beef Nutrition 0.000 title claims description 31
230000001965 increasing effect Effects 0.000 title claims description 28
238000000034 method Methods 0.000 title claims description 23
108010006025 bovine growth hormone Proteins 0.000 claims description 135
239000000262 estrogen Substances 0.000 claims description 50
238000007912 intraperitoneal administration Methods 0.000 claims description 38
108010051696 Growth Hormone Proteins 0.000 claims description 35
102000018997 Growth Hormone Human genes 0.000 claims description 35
238000003307 slaughter Methods 0.000 claims description 29
230000037396 body weight Effects 0.000 claims description 18
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 15
229960005309 estradiol Drugs 0.000 claims description 14
229930182833 estradiol Natural products 0.000 claims description 10
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 7
230000002035 prolonged effect Effects 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 2
230000002459 sustained effect Effects 0.000 claims 1
238000011282 treatment Methods 0.000 description 36
239000000203 mixture Substances 0.000 description 33
241001465754 Metazoa Species 0.000 description 27
239000008188 pellet Substances 0.000 description 21
239000007943 implant Substances 0.000 description 20
229940011871 estrogen Drugs 0.000 description 19
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
238000009472 formulation Methods 0.000 description 18
230000003204 osmotic effect Effects 0.000 description 16
230000000694 effects Effects 0.000 description 14
229920005862 polyol Polymers 0.000 description 13
150000003077 polyols Chemical class 0.000 description 13
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
210000003200 peritoneal cavity Anatomy 0.000 description 12
239000000872 buffer Substances 0.000 description 10
239000000546 pharmaceutical excipient Substances 0.000 description 10
230000003247 decreasing effect Effects 0.000 description 8
238000007920 subcutaneous administration Methods 0.000 description 8
210000001835 viscera Anatomy 0.000 description 8
235000011187 glycerol Nutrition 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
-1 alanyl-valyl Chemical group 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
235000019786 weight gain Nutrition 0.000 description 6
230000007423 decrease Effects 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
230000037213 diet Effects 0.000 description 4
244000309465 heifer Species 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
238000002513 implantation Methods 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
238000005303 weighing Methods 0.000 description 4
230000004584 weight gain Effects 0.000 description 4
229960002300 zeranol Drugs 0.000 description 4
238000004458 analytical method Methods 0.000 description 3
229940061607 dibasic sodium phosphate Drugs 0.000 description 3
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
230000001076 estrogenic effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
210000000505 parietal peritoneum Anatomy 0.000 description 3
239000001103 potassium chloride Substances 0.000 description 3
235000011164 potassium chloride Nutrition 0.000 description 3
230000004044 response Effects 0.000 description 3
210000004767 rumen Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
210000000504 visceral peritoneum Anatomy 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
239000011701 zinc Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
210000003815 abdominal wall Anatomy 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000001174 ascending effect Effects 0.000 description 2
230000003385 bacteriostatic effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
235000012206 bottled water Nutrition 0.000 description 2
244000309466 calf Species 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
235000013365 dairy product Nutrition 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
210000001198 duodenum Anatomy 0.000 description 2
229950002007 estradiol benzoate Drugs 0.000 description 2
229940106582 estrogenic substances Drugs 0.000 description 2
229960003399 estrone Drugs 0.000 description 2
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
210000004303 peritoneum Anatomy 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
230000000541 pulsatile effect Effects 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000009467 reduction Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
BFPYWIDHMRZLRN-SWBPCFCJSA-N (8r,9s,13s,14s,17s)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SWBPCFCJSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
KDPQTPZDVJHMET-UHFFFAOYSA-N 3-acetoxy-1,3,5(10)-estratrien-17-one Natural products C1CC2(C)C(=O)CCC2C2CCC3=CC(OC(=O)C)=CC=C3C21 KDPQTPZDVJHMET-UHFFFAOYSA-N 0.000 description 1
PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
235000019750 Crude protein Nutrition 0.000 description 1
JQIYNMYZKRGDFK-RUFWAXPRSA-N Estradiol dipropionate Chemical compound C1CC2=CC(OC(=O)CC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 JQIYNMYZKRGDFK-RUFWAXPRSA-N 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
241000282849 Ruminantia Species 0.000 description 1
KDPQTPZDVJHMET-XSYGEPLQSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C[C@]2(C)C(=O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)C)=CC=C3[C@H]21 KDPQTPZDVJHMET-XSYGEPLQSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000007792 addition Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000001815 ascending colon Anatomy 0.000 description 1
235000021052 average daily weight gain Nutrition 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
150000001879 copper Chemical class 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000001731 descending colon Anatomy 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229950010215 estradiol dipropionate Drugs 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
210000000569 greater omentum Anatomy 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
229950001996 hexestrol Drugs 0.000 description 1
210000001981 hip bone Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000000003 hoof Anatomy 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
230000035800 maturation Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002151 serous membrane Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000003384 transverse colon Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Fodder In General (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL11440995A 1994-07-01 1995-06-30 A method of increasing the effective percentage of weight in animals after slaughter in the final stage of breeding IL114409A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/269,986 US5595752A (en)	1994-07-01	1994-07-01	Increasing dressing percentage and carcass weight in finishing beef cattle

Publications (2)

Publication Number	Publication Date
IL114409A0 IL114409A0 (en)	1995-10-31
IL114409A true IL114409A (en)	1998-12-27

Family

ID=23029417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11440995A IL114409A (en)	1994-07-01	1995-06-30	A method of increasing the effective percentage of weight in animals after slaughter in the final stage of breeding

Country Status (8)

Country	Link
US (1)	US5595752A (fr)
EP (1)	EP0773792A1 (fr)
AU (1)	AU703299B2 (fr)
CA (1)	CA2193988A1 (fr)
IL (1)	IL114409A (fr)
MX (1)	MX9700227A (fr)
WO (1)	WO1996001123A1 (fr)
ZA (1)	ZA955456B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA9711731B (en)	1996-12-31	1998-07-01	Monsanto Co	Aqueous glycerol formulations of somatotropin
JP2002504932A (ja) *	1997-06-27	2002-02-12	モンサント・カンパニー	ソマトトロピンによる動物の蹄の成長促進
KR19990071255A (ko)	1998-02-28	1999-09-15	성재갑	소마토트로핀과 비타민의 합제 조성물

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1555711A (en) *	1921-10-26	1925-09-29	Harry B Hershinger	Grease gun
US1642950A (en) *	1927-02-24	1927-09-20	Earle C Haas	Medical-powder applicator
US1929154A (en) *	1931-07-29	1933-10-03	Sundock Rose	Powder spray and injector
US2059966A (en) *	1932-09-27	1936-11-03	Gynex Corp	Dispensing device
US2086580A (en) *	1935-06-24	1937-07-13	Myron C Shirley	Applicator
US2519555A (en) *	1945-08-31	1950-08-22	Abbott Lab	Sterile medicament insufflator cartridge and insufflator
US2587364A (en) *	1948-05-20	1952-02-26	Edith Mitchell	Balling gun
US2572155A (en) *	1949-10-01	1951-10-23	Robert H Hoyt	Vial for use in artificial insemination
US3016895A (en) *	1958-08-01	1962-01-16	Pan American Lab Inc	Injector for subcutaneous implantation of solids
US3140078A (en) *	1961-06-15	1964-07-07	Adhesive Eng Co	Mixing and dispensing device
US3144178A (en) *	1962-03-12	1964-08-11	Stanley J Sarnoff	Cartridge holder
US3141583A (en) *	1962-03-23	1964-07-21	William L Brickson	Injection gun
US3256884A (en) *	1963-04-15	1966-06-21	Hill	Injection device for artificial insemination having a disposable dispensing capsule with detachable actuator
US3348545A (en) *	1964-10-22	1967-10-24	Sarnoff	Latched cartridge
US3506008A (en) *	1968-03-25	1970-04-14	Ortho Pharma Corp	Medical applicator
US3620216A (en) *	1969-06-25	1971-11-16	Abbott Lab	Implant trocar
US3760804A (en) *	1971-01-13	1973-09-25	Alza Corp	Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
GB1525841A (en) *	1976-05-18	1978-09-20	Hundon Forge Ltd	Drug implanters
NZ197426A (en) *	1980-06-19	1984-07-06	Phillips Pty Ltd N J	Pellet gun:magazine indexed for next injection on retraction of indexing rod
US4557724A (en) *	1981-02-17	1985-12-10	University Of Utah Research Foundation	Apparatus and methods for minimizing cellular adhesion on peritoneal injection catheters
US4492576A (en) *	1982-06-15	1985-01-08	Dragan William B	Dental syringe and method of packaging and dispensing a dental material
US4452775A (en) *	1982-12-03	1984-06-05	Syntex (U.S.A.) Inc.	Cholesterol matrix delivery system for sustained release of macromolecules
US4576604A (en) *	1983-03-04	1986-03-18	Alza Corporation	Osmotic system with instant drug availability
GB8403138D0 (en) *	1984-02-07	1984-03-14	Graham N B	Sustained release of active ingredient
US4857534A (en) *	1984-04-05	1989-08-15	North Carolina State University	Method of maintaining ruminants on high energy low fiber diet
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes
US4891208A (en) *	1985-04-10	1990-01-02	The Liposome Company, Inc.	Steroidal liposomes
US4725439A (en) *	1984-06-29	1988-02-16	Alza Corporation	Transdermal drug delivery device
US4820267A (en) *	1985-02-19	1989-04-11	Endocon, Inc.	Cartridge injector for pellet medicaments
US4769011A (en) *	1985-03-28	1988-09-06	Interpore International, Inc.	Syringe apparatus and method for the surgical implantation of granular substances
US4670249A (en) *	1985-04-12	1987-06-02	International Minerals & Chemical Corp.	Growth-promoting compositions
US4624847A (en) *	1985-04-22	1986-11-25	Alza Corporation	Drug delivery device for programmed delivery of beneficial drug
US4786501A (en) *	1985-07-15	1988-11-22	International Minerals & Chemical Corp.	Cylindrical implants for the controlled release of growth hormones
US4863901A (en) *	1986-01-09	1989-09-05	Brigham & Women's Hospital	Use of growth hormone for nitrogen retention under hypocaloric conditions
US4917685A (en) *	1986-05-16	1990-04-17	International Minerals & Chem. Corp.	Delivery device for the administration of stabilized growth promoting hormones
US4723958A (en) *	1986-05-23	1988-02-09	Merck & Co., Inc.	Pulsatile drug delivery system
US4787384A (en) *	1986-10-06	1988-11-29	Bio Medic Data System, Inc.	Animal marker implanting system
US4997825A (en) *	1986-12-22	1991-03-05	Eli Lilly And Company	Synergistic treatment method
ES2019410B3 (es) *	1987-02-13	1991-06-16	Wilhelm A Keller	Cartucho de evacuacion con embolo impulsor
US4863736A (en) *	1987-03-16	1989-09-05	Monsanto Company	Somatotropin prolonged release
US4846793A (en) *	1987-03-18	1989-07-11	Endocon, Inc.	Injector for implanting multiple pellet medicaments
US4816439A (en) *	1987-03-27	1989-03-28	Nordiske Gentofte A/S	The use of human growth hormone for the treatment of intoxicated individuals
DE3802158A1 (de) *	1987-08-11	1989-02-23	Hoechst Ag	Vorrichtung zur applikation von implantaten
CA1336886C (fr) *	1988-03-07	1995-09-05	David Bennett Anderson	Combinaisons de phenethanolamine et d'hormone de croissance
US4959218A (en) *	1988-03-25	1990-09-25	Alza Corporation	Method for delivering somatotropin to an animal
EP0374120A3 (fr) *	1988-12-13	1991-07-31	Monsanto Company	Composition pour la libération contrôlée des polypeptides
US5057318A (en) *	1988-12-13	1991-10-15	Alza Corporation	Delivery system for beneficial agent over a broad range of rates
US5174999A (en) *	1988-12-13	1992-12-29	Alza Corporation	Delivery system comprising fluid ingress and drug egress
US5034229A (en) *	1988-12-13	1991-07-23	Alza Corporation	Dispenser for increasing feed conversion of hog
GB8829089D0 (en) *	1988-12-13	1989-01-25	Coopers Animal Health	Intra ruminal device
US5059423A (en) *	1988-12-13	1991-10-22	Alza Corporation	Delivery system comprising biocompatible beneficial agent formulation
US5110596A (en) *	1988-12-13	1992-05-05	Alza Corporation	Delivery system comprising means for delivering agent to livestock
US5135523A (en) *	1988-12-13	1992-08-04	Alza Corporation	Delivery system for administering agent to ruminants and swine
US5037420A (en) *	1988-12-13	1991-08-06	Alza Corporation	Delivery system comprising two sections for delivering somatotropin
US4923096A (en) *	1989-01-09	1990-05-08	Mark L. Anderson	Dripless automatic syringe for dispensing fluids
US5219572A (en) *	1989-03-17	1993-06-15	Pitman-Moore, Inc.	Controlled release delivery device for macromolecular proteins
NL8901281A (nl) *	1989-05-23	1990-12-17	Nedap Nv	Implanteernaald met axiale spleet.
US5035897A (en) *	1989-09-05	1991-07-30	Alza Corporation	Dosage form for delivering soluble or insoluble drugs
US5112614A (en) *	1989-09-14	1992-05-12	Alza Corporation	Implantable delivery dispenser
US5100392A (en) *	1989-12-08	1992-03-31	Biosynthesis, Inc.	Implantable device for administration of drugs or other liquid solutions
US5045082A (en) *	1990-01-10	1991-09-03	Alza Corporation	Long-term delivery device including loading dose
US5223266A (en) *	1990-01-24	1993-06-29	Alza Corporation	Long-term delivery device with early startup
US5156851A (en) *	1990-06-20	1992-10-20	Monsanto Company	Coated veterinary implants
US5091185A (en) *	1990-06-20	1992-02-25	Monsanto Company	Coated veterinary implants
US5232708A (en) *	1990-06-20	1993-08-03	Monsanto Company	Coated veterinary implants
US5238687A (en) *	1990-07-11	1993-08-24	Alza Corporation	Delivery device with a protective sleeve
US5234694A (en) *	1990-07-11	1993-08-10	Alza Corporation	Method for increasing feed efficiency in animals
US5180591A (en) *	1990-07-11	1993-01-19	Alza Corporation	Delivery device with a protective sleeve
US5234692A (en) *	1990-07-11	1993-08-10	Alza Corporation	Delivery device with a protective sleeve
US5234693A (en) *	1990-07-11	1993-08-10	Alza Corporation	Delivery device with a protective sleeve
US5801716A (en) *	1990-08-16	1998-09-01	Canon Kabushiki Kaisha	Pipeline structures for full-color computer graphics
PT100221A (pt) *	1991-03-12	1994-05-31	Alza Corp	Dispositivo de libertacao de um agente activo eficiente relativamente ao espaco e a estabilidade
US5227167A (en) *	1991-06-11	1993-07-13	Alza Corporation	Long-term delivery device including hydrophobic loading dose
US5137727A (en) *	1991-06-12	1992-08-11	Alza Corporation	Delivery device providing beneficial agent stability
US5209746A (en) *	1992-02-18	1993-05-11	Alza Corporation	Osmotically driven delivery devices with pulsatile effect
US5312333A (en) *	1992-04-03	1994-05-17	United States Surgical Corporation	Endoscopic material delivery device
US5281197A (en) *	1992-07-27	1994-01-25	Symbiosis Corporation	Endoscopic hemostatic agent delivery system
AU4986393A (en) *	1992-08-19	1994-03-15	Massey University	Methods for effecting a prolonged reduction in measurable fat content and medicaments for use therein
FR2694885B1 (fr) *	1992-08-20	1994-10-07	Rhone Merieux	Procédé pour améliorer la croissance et la qualité des carcasses des animaux domestiques producteurs de viande, ensemble de vaccination et vaccins.
US5292307A (en) *	1992-09-16	1994-03-08	Dolzine Theodore W	Dispensing package for unit dosage
US5304119A (en) *	1993-06-24	1994-04-19	Monsanto Company	Instrument for injecting implants through animal hide

1994
- 1994-07-01 US US08/269,986 patent/US5595752A/en not_active Expired - Fee Related
1995
- 1995-06-30 IL IL11440995A patent/IL114409A/en not_active IP Right Cessation
- 1995-06-30 MX MX9700227A patent/MX9700227A/es unknown
- 1995-06-30 ZA ZA955456A patent/ZA955456B/xx unknown
- 1995-06-30 CA CA002193988A patent/CA2193988A1/fr not_active Abandoned
- 1995-06-30 EP EP95925429A patent/EP0773792A1/fr not_active Ceased
- 1995-06-30 WO PCT/US1995/008309 patent/WO1996001123A1/fr not_active Application Discontinuation
- 1995-06-30 AU AU29563/95A patent/AU703299B2/en not_active Ceased

Also Published As

Publication number	Publication date
MX9700227A (es)	1997-05-31
US5595752A (en)	1997-01-21
AU2956395A (en)	1996-01-25
WO1996001123A1 (fr)	1996-01-18
EP0773792A1 (fr)	1997-05-21
AU703299B2 (en)	1999-03-25
ZA955456B (en)	1996-05-14
IL114409A0 (en)	1995-10-31
CA2193988A1 (fr)	1996-01-18

Publication	Publication Date	Title
Barbul et al.	1983	Wound healing and thymotropic effects of arginine: a pituitary mechanism of action
US7037516B2 (en)	2006-05-02	Non-aqueous surfactant-containing formulations for extended release of somatotropin
Vernon et al.	1981	Metabolism of sheep adipose tissue during pregnancy and lactation. Adaptation and regulation
JP2664398B2 (ja)	1997-10-15	徐放性ソマトトロピンおよび投与方法
CZ815687A3 (cs)	1998-09-16	Nevodný prostředek na somatotropinové bázi
MALAISSE et al.	1969	Effects of pregnancy and chorionic growth hormone upon insulin secretion
EP0374120A2 (fr)	1990-06-20	Composition pour la libération contrôlée des polypeptides
US5292721A (en)	1994-03-08	Use of growth hormone to enhance porcine fetal energy and sow lactation performance
JP2620417B2 (ja)	1997-06-11	生物学的活性を有するポリペプチドを持続的に放出する組成物
Azain et al.	1995	Comparison of daily versus continuous administration of somatotropin on growth rate, feed intake, and body composition in intact female rats
JPH0561252B2 (fr)	1993-09-06
US5610138A (en)	1997-03-11	Process for treating infertility and an agent for use in the process
JPH05503702A (ja)	1993-06-17	卵胞の成熟を阻害する方法
US5595752A (en)	1997-01-21	Increasing dressing percentage and carcass weight in finishing beef cattle
Gomez et al.	1937	Hypophysectomy and replacement therapy in relation to the growth and secretory activity of the mammary gland
US20040087495A1 (en)	2004-05-06	Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
US6719990B2 (en)	2004-04-13	Non-aqueous injectable formulations for extended release of somatotropin
AU643073B2 (en)	1993-11-04	Treatment of human lactation failure
US4997825A (en)	1991-03-05	Synergistic treatment method
CHIANG et al.	1991	Administration of growth hormone to pregnant rats on a reduced diet inhibits growth of their fetuses
Dubreuil et al.	1990	Influence of growth hormone-releasing factor and (or) thyrotropin-releasing factor on sow blood components, milk composition and piglet performance
KR100355517B1 (ko)	2003-03-04	수성의지속성방출제제
KR0152082B1 (ko)	1998-10-15	소마토트로핀 조성물
EP0272890B1 (fr)	1992-07-15	Méthode de traitement synergique
CA2101357A1 (fr)	1994-02-04	Methode veterinaire

Legal Events

Date	Code	Title
1999-06-20	FF	Patent granted
2000-06-01	KB	Patent renewed
2002-02-10	MM9K	Patent not in force due to non-payment of renewal fees